

Original Research Article

Prevalence of three prothrombotic genes polymorphisms: Factor II, Factor V and MTHFR in referred population of Gujarat.

ABSTRACT

Aim: To study the prevalence of major mutations associated with VTE in referred individuals at Gujarat.

Place and Duration of Study: PanGenomics International, Sterling Accuris Diagnostics, Ahmedabad, Gujarat, India between June 2020 to December 2021.

Methodology: 121 individuals referred for thrombosis genetic test were included in the study. Among 121 subjects, 71 were male and 50 were female. SNP genotyping was performed with melt curve analysis and confirmed with sanger sequencing.

Results: Highest prevalent SNP was of MTHFR A1298C with allelic frequency of 36.78%. Factor V and MTHFR SNP allelic frequency was comparable to previous studies. Absence of Factor II mutant allele in the studied population was inconsistent with the population from other countries but supports previous studies with Indian population. Minor allele frequency for MTHFR A1298C mutation was high as 36.78% and C677T mutation was 13.22%. Factor V Leiden R506Q allele frequency was 2.89% and H1299R allele frequency was 9.50%.

Conclusion: Among various surveys conducted throughout the world, considerable variation in prevalence of Factor II, Factor V and MTHFR gene mutations have been found. The mutations studied here are major risk factors for thrombosis. Population-based prevalence study of these mutations may help in reflecting the burden of disease in studied population.

Keywords: Factor II, Factor V, MTHFR, Allelic frequency, Melt curve, Sanger Sequencing

1. INTRODUCTION

Venous thromboembolism (VTE) is a complex vascular disease with multifactorial pathogenesis that results in two major clinical manifestations, deep-vein thrombosis (DVT) and Pulmonary Embolism (PE) [1, 2]. It is an inherited blood-clotting disorder, that increases the affected individual's tendency to form abnormal blood clots that may block blood vessels. VTE is the third leading cause of cardiovascular death across the globe [3]. As per Centers for Disease Control and Prevention (CDC) VTE is a leading cause of preventable hospital death in the United States. As many as 70% of cases of VTE are preventable. In the US, VTE affects an estimated 900,000 people each year, leading to an estimated 60,000–100,000 deaths (CDC). The identification of various factors that contribute for thrombosis, particularly the role of coagulation disorders, has expanded the knowledge of venous thrombosis over the past years [4]. As these abnormalities are found to be frequent in general population, they will be detected in large number of population at the same time. As per the studies carried out by Centers of Disease Control and Prevention, several factors such as surgery, pregnancy, oral contraceptives, cancer, antiphospholipid antibodies as well as hereditary factors interact to promote the development of deep vein thrombosis and pulmonary embolism.

Acquired as well as hereditary factors interact to promote deep vein thrombosis (DVT) and pulmonary embolism (PE). Acquired factors mainly include pregnancy, contraceptives, surgery, cancer, immobilization, antiphospholipid antibodies. Hereditary factors that induce VTE development can be classified as Protein C and Protein S deficiencies and polymorphisms [5]. In recent years, Factor V, MTHFR, and Prothrombin mutations were found to be responsible for producing Activated Protein C Resistance (APC R), hyperhomocysteinemia and increasing levels of Factor II respectively [6].

Factor V Leiden is a genetic disorder where activity of activated Protein C against coagulation factor V diminish which increases the risk for VTE. The F5 gene provides instructions for making a protein called coagulation factor V; this protein plays a critical role in the coagulation cascade. Variant detected in the F5 gene is a single nucleotide polymorphism (SNP) located at exon 10. A missense substitution of base G to base A changes the protein's amino acid from arginine to glutamine (c.G1691A or p.R506Q). Since this amino acid is normally the cleavage site for APC, the mutation prevents efficient inactivation of factor V. The coagulation system is controlled by several proteins, including one called activated protein C (APC). Under normal circumstances, APC inactivates coagulation factor V and which slows down the clotting process, preventing clots from growing too large. However, in people with factor V Leiden thrombophilia, coagulation factor V cannot be inactivated normally by APC. As a result, the clotting process remains active longer than usual, increasing the chance of developing abnormal blood clots [7].

MTHFR (methylenetetrahydrofolate reductase) is an enzyme involved in the metabolism of folate and homocysteine[8]. It plays a role in maintaining cellular folate levels. It is also a cofactor needed to convert homocysteine to methionine. Two common variants have been characterized that reduce the function of the MTHFR enzyme [9]. These are the c.C677T variant which is a change from cytosine to thymine at position 655 within the gene and the c.A1298C variant which is a change from adenine to cytosine at position 1286 within the gene. Reduced MTHFR enzyme activity can lead to elevated homocysteine levels, which is a known independent risk factor for development of cardiovascular disease and venous thrombosis. Reduced enzyme function can also affect folate levels and risk for recurrent pregnancy loss and neural tube defects in the fetus [10].

Coagulation factor II is the precursor of thrombin, which participates as a serine protease (factor II) in the coagulation cascade. The gene that codes for prothrombin has been mapped on chromosome 11 at position 11p11-q12. The prothrombin c.G20210A mutation is associated with a 3-fold increase in the risk of VTE. High Factor II plasma levels associated with this mutation are believed to be responsible for the increased risk of VTE[11]. According to the findings, Factor II plasma levels have a considerable influence on thrombin production, which is important for hemostasis and thrombosis.

The prevalence of these SNPs varies depending on geographical location and ethnic background of the population. Contrary to earlier belief, the incidence of VTE in India is comparable to that in Western countries. In the present study, allelic frequency of polymorphisms related to VTE is investigated in referred individuals from Gujarat. To the best of our knowledge, there are no previous reports which assess these five SNP frequencies dedicatedly in the Gujarat population.

2. MATERIAL AND METHODS

2.1 Sample collection

Blood samples were collected from 121 referred individuals at Sterling Accuris Diagnostics laboratory from all the different regions of Gujarat. Approximately 3-4ml blood was obtained from the individuals in a labeled sterile ethylenediaminetetraacetate (EDTA) vacutainer and were kept at -4°C for DNA extraction.

2.2 DNA Extraction

Genomic DNA isolation was done from the blood samples using QIAamp DNA Mini Kit. DNA was extracted from 200 µl using whole blood using the spin columns provided in the kit. The isolated DNA was stored at -20°C.

2.3 Sanger Sequencing based detection of mutations

The primers listed in Table 1 were used for PCR amplification Factor II, Factor V and MTHFR genes products. All the primers were tagged with M13 sequence at 5' end. PCR products were treated with Exosap-IT at 37°C for 15min and 80°C for 15 min using ABI Veriti thermal cycler. Cycle sequencing was performed with M13 primers using the following reaction mix - 1.8µl of 5X sequencing buffer, 0.5 µl of RR100 (BDT), 1 µl of M13 forward or reverse primer, 0.5 µl of Exosap treated product and 6.2 µl of milliQ. Cycle sequencing products were analyzed with ABI3500 Genetic Analyzer. Further, the sequences obtained were then analyzed using Chromaslite software, by comparing them with the reference sequences.

Table 1: Primers used in the study.

Gene	Primer Name	Primer Sequence (5'-3')	Product Size
Factor II	FTR-II-1F	5'TGTAAAACGACGGCCAGTATGTGTTCCGCC TGAAGAAG3'	275 bp
	FTR-II-1R	5'CAGGAAACAGCTATGACCAGTGCTCGGACT CCAGCGT3'	
Factor V	FTR-V-1F	5'TGTAAAACGACGGCCAGTTGTTATCACACTG GTGCTAA3'	345 bp
	FTR-V-1R	5'CAGGAAACAGCTATGACCGATCAGAGCAGT TCAACCA3'	
MTHFR	MTHFR-1F	5'TGTAAAACGACGGCCAGTCTCAAGGCAGGA CAGTGT3'	581 bp
	MTHFR-1R	5'CAGGAAACAGCTATGACCAAGAACTCAGCG AACTCAGCAC3'	
	MTHFR-2F	5'TGTAAAACGACGGCCAGTGACAGACCTTCCT TGCAAATAC3'	491 bp
	MTHFR-2R	5'CAGGAAACAGCTATGACCTTGCCATGTCCA CAGCAT3'	
M13	M13 – F	5'TGTAAAACGACGGCCAGT3'	
	M13 – R	5'CAGGAAACAGCTATGACC3'	

2.4 Real-Time PCR based detection of mutations

Anyplex™ II SNP panel assay is a real-time PCR based assay. This assay was used for the study of the six thrombosis-associated single nucleotide polymorphisms (SNPs): Factor II (G20210A), Factor V (R506Q, H1299R, Y1702C) and MTHFR (C677T, A1298C). Real-time PCR detection of these SNPs was performed using Qiagen real-time thermal cycler- Rotor-Gene Q. A total system of 20 µl per reaction was set which incorporated 15 µl of master mix and 5 µl of DNA template. The thermal cycle and fluorophores were set according to the protocol provided by the kit manufacturer. Once the amplification cycles were completed, the mutations were determined by melt curve analysis as represented in Figure 1.




Figure-1: Melt-curve analysis of Anyplex^{II} thrombosis SNP panel assay.

3. RESULTS

Among three genes, MTHFR allele mutation was the most prevalent. From a total of 121 samples, 53 samples were heterozygous and 13 samples were homozygous for A1298C mutation. Thus, mutant allele for A1298C was widely present in Gujarat population accounting for allelic frequency of 36.78%. Figure-2 is a representative electrogram of wild type and mutant alleles found in the study. MTHFR C677T mutation was also highly prevalent with 16 heterozygous and 3 homozygous cases. The allele frequency was 13.22% for C677T mutation. Also, 8 out of 121 cases were heterozygous and 1 case was homozygous for both the mutation. Among 121 subjects, 71 were male and 50 were female. Upon analyzing the data from Table-2, there was no difference among male and female allelic frequency.

Surprisingly, none of the samples were found positive for Factor II mutation. 21 individuals were found with H1299R heterozygous mutation and only 1 individual was homozygous. In case of R506Q mutation, 7 cases were heterozygous and there was no homozygous case. Thus Factor V mutant allele was less prevalent compared to MTHFR mutation. Allelic frequency of H1299R was 9.50% and R506Q was 2.89%.




Figure-2: Image electrogram of Factor II, Factor V and MTHFR genes point mutations. (a) Factor II WT, (b) Factor V WT, (c) Factor V R506Q heterozygous, (d) MTHFR C677T WT, (e) C677T heterozygous, (f) C677T homozygous, (g) MTHFR A1286C WT, (h) A1298C heterozygous, (i) A1298C homozygous.

Table 2 : Distribution of thrombotic genes mutation in Gujarat Population.

MTHFR	Female	Male	Total
WT	7	20	27
A1298C(HET)	25	28	53
A1298C(HM)	5	8	13
C677T(HET)	10	6	16
C677T(HM)	0	3	3
Compound mutation			
C677T(HET), A1298C(HET)	3	5	8
C677T(HM), A1298C(HM)	0	1	1
Total	50	71	121
Factor V			
WT	37	55	92
H1299R(HET)	10	11	21
H1299R(HM)	0	1	1
R506Q(HET)	3	4	7
Total	50	71	121
Factor II			
WT	50	71	121

4. DISCUSSION

Several studies have been conducted demonstrating considerable variations of the prevalence of venous thromboembolism associated genes. Major genetical cause for VTE accounts for polymorphisms with Factor II (G20210A), Factor V (R506Q, H1299R) and MTHFR (C677T, A1298C) genes [6].

Factor V Leiden, rs6025 (c.G1691A or p.R506Q), is point mutation and most frequently associated with VTE. Heterozygous individuals have 5 times and homozygous individuals have 10 times higher risks of developing VTE. European population have mutant allele frequency of 4-7% with highest prevalence in Greece (7%) [12]. West Bank population has high mutation frequency of 11% [13]. In a study conducted on South Indian population, 8 out of 240 samples (3.33%) found positive for Factor V Leiden [14]. Factor V gene polymorphism (His1299Arg; also named HR2) has also been reported as a risk factor for the development of VTE. H1229R mutant allele frequency in Lebanese population was around 6% [15] and Saudi-Arabia population had 5% [16]. There are no reports to our knowledge, indicating H1229R mutation prevalence in Indian population. In our study, Factor V Leiden, R506Q, mutant allele frequency was 2.89% and H1299R allele frequency was 9.50%.

Factor II polymorphism (G20210A) is associated with a higher risk of venous and arterial thrombosis in various studies. The polymorphism causes high plasma levels factor II which is a coagulation factor. There is 2.8 times higher risk of VTE in individuals with factor II polymorphism. In a study conducted in Argentina, 2.6% of samples were heterozygous for G20210A mutation [17]. In Indian Tamilian population, none of the samples had mutant allele among 72 subjects tested. In our study as well, mutant allele for G20210A mutation

was not detected. The ethnic background of Indians, as well as geographical locations, are plausible factors resulting in the complete absence of mutant allele for Factor II in both the studies.

Mutation c.C677T and c.A1298C in MTHFR gene results in a thermolabile variant with reduced enzymatic activity. Decreased MTHFR enzyme activity slows down the homocysteine-to-methionine conversion process and can lead to a buildup of homocysteine in the blood. MTHFR mutation is found to increase VTE risk by 2.5-fold [10, 18]. A study conducted by All India Institute of Medical Sciences found mutant allele frequency of MTHFR C677T and A1298C was 15% and 44% respectively in Indian population[19]. A targeted study for C677T mutation at Eastern Uttar Pradesh found T allele frequency of 12%[20]. The minor allele frequency was also calculated in this study from the data presented in Table-3 where the frequency of 13.22% for C677T and 36.78% for A1298C was obtained.

Table 3: Allelic frequency of Factor II, Factor V and MTHR genes SNPs.

SNP		Minor allele frequency
MTHFR	A1298C	C (0.37)
	C677T	T (0.13)
Factor II	G20210A	A (0.00)
Factor V	R506Q/G1691A	A (0.029)
	H1299R	A (0.095)

5. CONCLUSION

The SNPs analyzed in the present study, are major genetic risk factors for vascular diseases leading to thrombosis. Thrombosis may lead to several complications such as pulmonary embolism, cardiovascular disorders and pregnancy-related conditions such as fetal growth retardation and even stillbirth. The minor allele frequency for Factor V R506Q mutation was 2.9% and H1299R was 9.5%, for MTHFR C677T mutation was 13.22% and A1298C was 36.78%. Mutant allele for Factor II G20210A was not observed. The present study in referred subjects of Gujarat may contribute to a better understanding of genetic risk factors and burden of the thrombosis and other related disorders.

COMPETING INTERESTS DISCLAIMER:

Authors have declared that no competing interests exist. The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

REFERENCES

1. Hyers TM. Venous thromboembolism. *American Journal of Respiratory and Critical Care Medicine*. 1999;159:1–14. doi:10.1164/ajrccm.159.1.9803109.
2. Moheimani F, Jackson DE. Venous Thromboembolism: Classification, Risk Factors, Diagnosis, and Management. *ISRN Hematol*. 2011;2011:1–7. doi:10.5402/2011/124610.
3. Wendelboe AM, Raskob GE. Global Burden of Thrombosis: Epidemiologic Aspects. *Circ Res*. 2016;118:1340–7. doi:10.1161/CIRCRESAHA.115.306841.
4. Previtali E, Bucciarelli P, Passamonti SM, Martinelli I. Risk factors for venous and arterial thrombosis. *Blood Transfus*. 2011;9:120. doi:10.2450/2010.0066-10.
5. Mahmoodi BK, Brouwer JLP, Veeger NJGM, Van Der Meer J. Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age. Results from a large family cohort study. *Circulation*. 2008;118:1659–67. doi:10.1161/CIRCULATIONAHA.108.780759.
6. Genoud V, Castañón M, Annichino-Bizzacchi J, Korin J, Kordich L. Prevalence of Three Prothrombotic Polymorphisms: Factor V G1691A, Factor II G20210A and Methylenetetrahydrofolate Reductase (MTHFR) C 677T in Argentina. *Thromb Res*. 2000;100:127–31. doi:10.1016/S0049-3848(00)00314-5.
7. Kujovich JL. Factor v Leiden thrombophilia. *Genetics in Medicine*. 2011;13:1–16. doi:10.1097/GIM.0b013e3181faa0f2.
8. Leclerc D, Sibani S, Rozen R. Molecular Biology of Methylenetetrahydrofolate Reductase (MTHFR) and Overview of Mutations/Polymorphisms. 2013. <https://www.ncbi.nlm.nih.gov/books/NBK6561/>. Accessed 5 Oct 2021.
9. Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE. Biological and clinical implications of the MTHFR C677T polymorphism. *Trends in Pharmacological Sciences*. 2001;22:195–201.
10. Bansal P. Factor V Leiden and MTHFR mutations as a combined risk factor for hypercoagulability in referred Patients population from Western India. *Mol Cytogenet*. 2014;7:P28. doi:10.1186/1755-8166-7-S1-P28.
11. Martinelli I, Bucciarelli P, Mannucci PM. Thrombotic risk factors: Basic pathophysiology. *Critical Care Medicine*. 2010;38 SUPPL. 2. doi:10.1097/CCM.0b013e3181c9cbd9.
12. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. *Lancet*. 1995;346:1133–4. doi:10.1016/S0140-6736(95)91803-5.
13. Hussein A. High prevalence of three prothrombotic polymorphisms among Palestinians: factor V G1691A, factor II G20210A and methylenetetrahydrofolate reductase C677T. *J Thromb Thrombolysis*. 2012;34:383–7. doi:10.1007/S11239-012-0731-9.
14. Anadure R, Christopher R, Nagaraja D, Narayanan C. A genetic study of Factor V Leiden (G1691A) mutation in young ischemic strokes with large vessel disease in a South Indian population. *J Clin Neurosci*. 2017;44:346–52. doi:10.1016/j.jocn.2017.06.050.
15. Zaatari GS, Otrock ZK, Sabbagh AS, Mahfouz RAR. Prevalence of factor V R2 (H1299R) polymorphism in the Lebanese population. *Pathology*. 2006;38:442–4.

16. Awad NS, El-Tarras AES. Prevalence of H1299R polymorphism in the Factor v gene among the Taif-Saudi Arabia population using polymerase chain reaction-reverse hybridization technique. *Mol Biol Rep.* 2012;39:439–43. doi:10.1007/s11033-011-0756-8.
17. Angeline T, Bentley HA, Hawk AB, Manners RJ, Mokashi HA, Jeyaraj N, et al. Prevalence of the Factor V G1691A and the Factor II/prothrombin G20210A gene polymorphisms among Tamilians. *Exp Mol Pathol.* 2005;79:9–13.
18. Sacchi E, Tagliabue L, Duca F, Mannucci PM. High frequency of the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene in Northern Italy. *Thrombosis and haemostasis.* 1997;78:963–4.
19. Kumar J, Das SK, Sharma P, Karthikeyan G, Ramakrishnan L, Sengupta S. Homocysteine levels are associated with MTHFR A1298C polymorphism in Indian population. *J Hum Genet.* 2005;50:655–63. doi:10.1007/s10038-005-0313-1.
20. Rai V, Yadav U, Kumar P. Prevalence of methylenetetrahydrofolate reductase C677T polymorphism in eastern Uttar Pradesh. *Indian J Hum Genet.* 2012;18:43. doi:10.4103/0971-6866.96645.

Did the authors measure the yield and purity of DNA with the NanoDrop spectrophotometer ? If the measurement has been made, the author should write it in the material method section. Authors could defined the exclusion and inclusion criteria in detail in the method section.

The last sentence in the discussion section should be written in the result section. Similarly table 3 should be placed in result section.

Authors should correct spelling mistakes